[HTML][HTML] Origin and therapies of osteosarcoma
B Moukengue, M Lallier, L Marchandet, M Baud'huin… - Cancers, 2022 - mdpi.com
Simple Summary Osteosarcoma is the most common malignant bone tumor in children, with
a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the …
a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the …
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing
calcified osteoid extracellular matrix and inducing lung metastases with a high frequency …
calcified osteoid extracellular matrix and inducing lung metastases with a high frequency …
Increased prevalence of bisphosphonate‐related osteonecrosis of the jaw with vitamin D deficiency in rats
Necrotic bone exposure in the oral cavity has recently been reported in patients treated with
nitrogen‐containing bisphosphonates as part of their therapeutic regimen for multiple …
nitrogen‐containing bisphosphonates as part of their therapeutic regimen for multiple …
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
PA Meyers, JH Healey, AJ Chou, LH Wexler… - Cancer, 2011 - Wiley Online Library
BACKGROUND: This study evaluated the safety and feasibility of the addition of
pamidronate to chemotherapy for treatment of osteosarcoma. METHODS: The authors …
pamidronate to chemotherapy for treatment of osteosarcoma. METHODS: The authors …
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma
KH Lu, EWH Lu, CW Lin, JS Yang, SF Yang - Pharmacology & Therapeutics, 2020 - Elsevier
Osteosarcoma is the most common primary malignant tumor of the skeleton in teenagers
and young adults and continues to confer a generally poor prognosis in patients who do not …
and young adults and continues to confer a generally poor prognosis in patients who do not …
[HTML][HTML] The immune landscape of osteosarcoma: implications for prognosis and treatment response
C Cascini, C Chiodoni - Cells, 2021 - mdpi.com
Osteosarcoma (OS) is a high-grade malignant stromal tumor composed of mesenchymal
cells producing osteoid and immature bone, with a peak of incidence in the second decade …
cells producing osteoid and immature bone, with a peak of incidence in the second decade …
Bone sarcomas in the immunotherapy era
MF Heymann, K Schiavone… - British Journal of …, 2021 - Wiley Online Library
Bone sarcomas are primary bone tumours found mainly in children and adolescents, as
osteosarcoma and Ewing's sarcoma, and in adults in their 40s as chondrosarcoma. The last …
osteosarcoma and Ewing's sarcoma, and in adults in their 40s as chondrosarcoma. The last …
[HTML][HTML] Innate immune cells: a potential and promising cell population for treating osteosarcoma
Z Wang, Z Wang, B Li, S Wang, T Chen… - Frontiers in …, 2019 - frontiersin.org
Advanced, recurrent, or metastasized osteosarcomas remain challenging to cure or even
alleviate. Therefore, the development of novel therapeutic strategies is urgently needed …
alleviate. Therefore, the development of novel therapeutic strategies is urgently needed …
[HTML][HTML] T-cell-based immunotherapy for osteosarcoma: challenges and opportunities
Z Wang, B Li, Y Ren, Z Ye - Frontiers in immunology, 2016 - frontiersin.org
Even though combining surgery with chemotherapy has significantly improved the prognosis
of osteosarcoma patients, advanced, metastatic, or recurrent osteosarcomas are often non …
of osteosarcoma patients, advanced, metastatic, or recurrent osteosarcomas are often non …
The current and future therapies for human osteosarcoma
JD Lamplot, S Denduluri, J Qin, R Li… - Current cancer …, 2013 - ingentaconnect.com
Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults
and children. As sarcomas are more common in adolescents and young adults than most …
and children. As sarcomas are more common in adolescents and young adults than most …